Date:	3/28/2024
Your Name:	Daniel W. Sirkis
Manuscript Title:	Expansion of highly interferon-responsive T cells in early-onset Alzheimer's disease
Manuscript Number (if known):	ADJ-D-23-01733

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None Time frame: past 36 month	Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	[⊠] None	
3	Royalties or licenses	None Non	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	Rainwater Charitable Foundation	Support for attending FTD Center Without Walls meeting, UCLA, 10/2023
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	3/18/2024
Your Name:	Caroline Warly Solsberg
Manuscript Title:	Expansion of highly interferon-responsive T cells in early-onset Alzheimer's disease
Manuscript Number (if known):	ADJ-D-23-01733

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	NIH Intramural Center for Alzheimer's and Related Dementias (CARD), project NIH-NIA ZIAAG000534 Time frame: past 36 months	Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	[⊠] None	
3	Royalties or licenses	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	3/25/2024
Your Name:	Taylor Patrick Johnson
Manuscript Title:	Expansion of highly interferon-responsive T cells in early-onset Alzheimer's disease
Manuscript Number (if known):	ADJ-D-23-01733

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	[⊠] None	Click the tab key to add additional rows.
		Time frame: past 36 month	hs
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	3/22/2024
Your Name:	Luke Bonham
Manuscript Title:	Expansion of highly interferon-responsive T cells in early-onset Alzheimer's disease
Manuscript Number (if known):	ADJ-D-23-01733

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as	
		Time frame: Since the initia	l planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	[⊠] None	Click the tab key to add additional rows.
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	[⊠] None	
3	Royalties or licenses	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	March 28, 2024
Your Name:	Alexis Oddi
Manuscript Title:	Expansion of highly interferon-responsive T cells in early-onset Alzheimer's disease
Manuscript Number (if known):	ADJ-D-23-01733

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial planni	ng of the work Click the tab key to add additional rows.
		Time frame: past 36 mor	ths
2	Grants or contracts from any entity (if not indicated in item #1 above).	[⊠] None	
3	Royalties or licenses	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	3/22/2024
Your Name:	Ethan Geier
Manuscript Title:	Expansion of highly interferon-responsive T cells in early-onset Alzheimer's disease
Manuscript Number (if known):	ADJ-D-23-01733.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as	
		Time frame: Since the initia	l planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	[⊠] None	Click the tab key to add additional rows.
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	[⊠] None	
3	Royalties or licenses	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	3/21/2024
Your Name:	Bruce L. Miller
Manuscript Title:	Expansion of highly interferon-responsive T cells in early onset Alzheimer's disease
Manuscript Number (if known):	ADJ-D-23-01733

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

I		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g.,	□ None	D01 A C010734
	funding, provision	NIH/NIA NIH/NIA	P01 AG019724 R01 AG057234
	of study materials,	Bluefield Project to Cure FTD	P0544014
	article processing charges, etc.) No time limit for this item.	Time frame: past 36 mont	hs
2	Grants or contracts from	□ None	
	any entity (if not	NIH/Univ. of Wisconsin, Madison	1R01AG070883
	indicated in item	NIH/NIA	R35AG072362
	#1 above).	Bluefield Project to Cure FTD, UCSF FTD Core	P0544014
		NIH/NIA	P30AG062422
		NIH/NIA	R01AG057234
		NIH/NIA	R01AG062562
		NIH/NIA	R01AG062588
	1	NIH CSR	R01AG052496

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	□ None	
		Cambridge University Press	Payment made to me
		Elsevier, Inc.	Payment made to me
		Guilford Publications, Inc.	Payment made to me
		Johns Hopkins Press	Payment made to me
		Oxford University Press	Payment made to me
		Taylor & Francis Group	Payment made to me
4	Consulting fees	□ None	
		Massachusetts General Hospital Alzheimer's Disease Research Center (ADRC) Scientific Advisory Board (SAB)	Payments made to me in 2021, 2022, and 2023
		Stanford University ADRC SAB	Payments made to me in 2021, 2022, and 2023
		University of Washington ADRC SAB	Payments made to me in 2021, 2022, and 2023
		Genworth Medical Advisory Board	Payment made to me in March 2023
5	Payment or honoraria for	□ None	
	lectures,	Fromm Institute for Lifelong Learning	May 2023, payment made to me
	presentations,	Global Summit on Neurodegenerative Diseases	Jun 2021, payment made to me
	speakers	Korean Dementia Society	Jul 2022, payment made to me
	bureaus,	Massachusetts General Hospital, dementia course	Payments made to me in 2022 and 2023
	manuscript	National MS Society, Don Paty Lectureship	Jun 2021, payment made to me
	writing or	Ochsner Neuroscience Institute	Nov 2021, payment made to me
	educational	Providence Saint Joseph Medical Center	Sep 2021, payment made to me
	events	Taipei Medical University, Dementia Center	Mar 2022, payment made to me
		UC Irvine Institute for Memory Impairments and Neurological Disorders (UCI MIND)	Mar 2022, payment made to me
		University of California, Los Angeles (UCLA) Grand Rounds	Apr 2022, payment made to me
		University of Texas, Center for Brain Health	Jan 2021, payment made to me
6	Payment for expert testimony	None ■	
7	Support for attending	[□] None	
	meetings and/or travel	The Association for Frontotemporal Degeneration (AFTD) Education Symposium, St. Louis, MO	May 2023, travel and lodging support
		Milken Institute FTD Scientific Retreat, Los Angeles, CA	Mar 2023, travel and lodging support
		California Institute of the Arts, Los Angeles, CA	Apr 2022, travel and lodging support
		UCLA	Apr 2022, travel and lodging support
			, , , , , , , , , , , , , , , , , , , ,

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	Arizona Alzheimer's Consortium Association for Frontotemporal Degeneration The Buck Institute for Research on Aging Cure ALS The John Douglas French Alzheimer's Foundation Fundación Centro de Investigación Enfermedades Neurológicas, Madrid, Spain Genworth Kissick Family Foundation The Larry L. Hillblom Foundation Massachusetts General Hospital ADRC National Institute for Health Research Cambridge Biomedical Research Center and its subunit, the Biomedical Research Unit in Dementia Stanford University ADRC University of Southern California P01 Urban Air Pollution and Alzheimer's Disease: Risk, Heterogeneity, and Mechanisms University of Washington ADRC	External Advisor Scientific Advisor Scientific Advisor Scientific Advisor Medical Advisor Scientific Advisor
11	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options	The Bluefield Project to Cure FTD Global Brain Health Institute Institute for Neurodegenerative Diseases Tau Consortium of the Rainwater Charitable Fdtn. None	Director and Internal Advisor Founding Director Affiliated Faculty Co-Director and Scientific Advisor
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
13	Other financial or non-financial interests	None	
Plea [⊠]	•	t to the following statement to indicate your agreeme answered every question and have not altered the wo	

Date:	3/21/2024
Your Name:	Gil D Rabinovici
Manuscript Title:	Expansion of highly interferon-responsive T cells in early-onset Alzheimer's disease
Manuscript Number (if known):	ADJ-D-23-01733

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None NIH/NIA NIH/NIA	P30AG062422 R35AG072362 Click the tab key to add additional rows.
		Time frame: past 36 montl	hs
2	Grants or contracts from any entity (if not indicated in item	None NIH-NIA R35AG072362, P30AG062422, U01AG057195, NIH-NINDS R21NS120629	Paid to institution
	#1 above).	Alzheimer's Association ZEN-21-848216, SG-21-876655	Paid to institution
		Grant from American College of Radiology/Alzheimer's Association, supported by Eli Lilly/Life Molecular Imaging/GE Healthcare	Paid to institution
		Grant from Alliance for Therapeutics in Neurodegeneration (supported by Genentech)	Paid to institution
		Rainwater Charitable Foundation	Paid to institution

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None	
4	Consulting fees	[□] None	
		Eli Lilly GE Healthcare Roche Genentech	Paid to me Paid to me Paid to me Paid to me
5	Payment or honoraria for lectures, presentations, speakers bureaus,	Efficient LLC Associate Editor – JAMA Neurology Miller Medical Communications	Paid to me Paid to me Paid to me
	manuscript writing or educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	Johnson & Johnson	Paid to me
10	Leadership or fiduciary role in other board,	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea [⊠]		t to the following statement to indicate your agreeme answered every question and have not altered the wo	

Date:	3/21/2024
Your Name:	Jennifer S. Yokoyama, PhD
Manuscript Title:	Expansion of highly interferon-responsive T cells in early-onset Alzheimer's disease
Manuscript Number (if known):	ADJ-D-23-01733

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g.,	□ None NIH	Institution (NIII NIA DO1 ACOCOTOR DO1
	funding, provision of study materials, medical writing,		Institution (NIH-NIA R01 AG062588, R01 AG057234, P30 AG062422; NIH-NINDS U54 NS123985, NIH-NIDA 75N95022C00031, NIH-NIA U19AG079774)
	article processing	Rainwater Charitable Foundation	Institution
	charges, etc.)	Alzheimer's Association	Institution
	No time limit for this item.	Global Brain Health Institute	Institution
	this item.	Mary Oakley Foundation	Institution
		Time frame: past 36 month	ns
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None ■	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Lecture: "Immune Contributions to Frontotemporal Dementia," Knight Initiative Symposium: Frontotemporal Dementia, Knight Initiative for Brain Resilience, Wu Tsai Neurosciences Institute, Stanford University, November 28, 2023 Grand Rounds: "Genetic Contributions to Neurodegenerative Disease," Department of Neurology, University of California Los Angeles, October 25, 2023 Lecture: "Immune Contributors to Neurodegenerative Disease," Washington University in St. Louis School of Medicine NeuroGenomics and Informatics Center, August 18, 2022 Lecture: Immune Contributors to Neurodegeneration," North Central Florida Society for Neuroscience Chapter Conference, January 28, 2022 Lecture: "Genetic Characterization of Neurodegenerative Diseases," The Ohio State University Inaugural Neurogenetics Symposium, September 24, 2021.	Payment to JSY directly Payment to JSY directly Payment to JSY directly Payment to JSY directly Payment to JSY directly
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
9	Participation on a Data Safety Monitoring Board or Advisory Board	□ None Epstein Family Alzheimer's Collaboration, University of California San Diego	Scientific Advisory Board member—payment made to institution
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Please place an "X" next to the following statement to indicate your agreement:			
[oxtimes]	□ I certify that I have answered every question and have not altered the wording of any of the questions on this form.		